Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ArQule
Biotech
Basilea returns cancer drug rights to Merck
Basilea Pharmaceutica will hand back a license for cancer drug derazantinib to Merck & Co. after determining it couldn’t hit the required terms.
Gabrielle Masson
Jun 27, 2022 11:18am
Mylan's Coury steps into exec chairman role—Chutes & Ladders
Apr 17, 2020 9:30am
Merck inks $2.7B ArQule deal, teeing up cancer race with Lilly
Dec 9, 2019 10:25am
Basilea posts interim data on ArQule-partnered cancer drug
Jan 9, 2019 9:50am
Basilea slots ArQule FGF drug into its cancer portfolio
Apr 17, 2018 9:37am
Liver cancer miss adds to litany of trial failures for ArQule's tivantinib
Mar 27, 2017 8:55am
